Summary
EudraCT Number: 2006-000977-31
Sponsor's Protocol Code Number: NV25361
National Competent Authority: Belgium - FPS Health-DGM 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2015-10-01
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000977-31/BE/

A. Protocol Information
A.1 Member State Concerned: Belgium - FPS Health-DGM
A.2 EudraCT number: 2006-000977-31
A.3 Full title of the trial: PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE
A.3.1 Title of the trial for lay people, in easily understood, i.e. non-technical, language: A Study of Pegasys in Combination with antiviral HBV oral Lamivudine or entecavir compared against no treatment in Children Positive but
tolerant to Chronic Hepatitis B.
A.4.1 Sponsor's protocol code number: NV25361
A.7 Trial is part of a Paediatric Investigation Plan: Yes
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: F. Hoffmann-La Roche Ltd
B.1.3.4	Country: Switzerland
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support: F. Hoffmann La Roche Ltd.
B.4.2 Country: Switzerland
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: F. Hoffmann-La Roche Ltd
B.5.2 Functional name of contact point: Trial Information Support Line-TISL
B.5.3 Address
B.5.3.1 Street Address: Grenzacherstrasse 124
B.5.3.2 Town/ city: Basel
B.5.3.3 Post code: 4070
B.5.3.4 Country: Switzerland
B.5.6 E-mail: global.rochegenentechtrials@roche.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Pegasys
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Ltd
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Pegasys
D.3.2 Product code: RO025-8310
D.3.4 Pharmaceutical form: Injection
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: PEGINTERFERON ALFA 2A
D.3.9.1 CAS number: 76543-88-9
D.3.9.2 Current sponsor code: RO025-8310/J13
D.3.10 Strength
D.3.10.1 Concentration unit: Âµg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 180 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: Yes
D.3.11.13.1 Other medicinal product type: Immunostimulating agent/cytokine
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Epivir
D.2.1.1.2 Name of the Marketing Authorisation holder: ViiV Healthcare UK Ltd.
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Epivir- Lamivudine
D.3.4 Pharmaceutical form: Oral solution
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: LAMIVUDINE
D.3.9.1 CAS number: 134678-17-4
D.3.9.4 EV Substance Code: SUB08392MIG
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 10 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: No
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Lamivudine
D.2.1.1.2 Name of the Marketing Authorisation holder: TEVA Pharma B.V
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Lamivudine
D.3.4 Pharmaceutical form: Film-coated tablet
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: LAMIVUDINE
D.3.9.1 CAS number: 134678-17-4
D.3.9.4 EV Substance Code: SUB08392MIG
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 100 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: No
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 4
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Baraclude
D.2.1.1.2 Name of the Marketing Authorisation holder: BRISTOL-MYERS SQUIBB PHARMA EEIG
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Baraclude
D.3.4 Pharmaceutical form: Oral solution
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: ENTECAVIR
D.3.9.1 CAS number: 209216-23-9
D.3.9.4 EV Substance Code: SUB21468
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 0.05 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: No
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 5
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Baraclude
D.2.1.1.2 Name of the Marketing Authorisation holder: BRISTOL-MYERS SQUIBB PHARMA EEIG
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Baraclude
D.3.4 Pharmaceutical form: Film-coated tablet
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: ENTECAVIR
D.3.9.1 CAS number: 209216-23-9
D.3.9.4 EV Substance Code: SUB21468
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 0.5 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: No
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Chronic Hepatitis B Virus infection
E.1.1.1 Medical condition in easily understood language: Chronic Hepatitis B  in immune-tolerant phase with high levels of hepatitis B virus in the blood and low (if any) liver damage
E.1.1.2 Therapeutic area: Diseases [C] - Virus Diseases [C02]
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 20.0
E.1.2 Level: LLT
E.1.2 Classification code: 10019743
E.1.2 Term: Hepatitis B virus (HBV)
E.1.2 System Organ Class: 100000004848
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To evaluate the efficacy of PegasysÂ® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.
E.2.2 Secondary objectives of the trial: â¢To evaluate efficacy of PegasysÂ® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.
â¢To evaluate efficacy of PegasysÂ® + lamivudine or entecavir in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBsAg, loss of HBeAg, HBV DNA levels at 1 year post-end of treatment.

E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: â¢ Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India)
â¢ Positive for HBsAg and HBeAg for more than 6 months prior to baseline
â¢ Detectable HBV-DNA (> 20,000 IU/mL as measured by PCR or hybridization) on at least 2 occasions at least one month apart with the latest determination obtained â¤ 42 days prior to baseline.

E.4 Principal exclusion criteria: Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded. 

E.5 End points
E.5.1 Primary end point(s): Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).
E.5.1.1 Timepoint(s) of evaluation of this end point: At 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80)
E.5.2 Secondary end point(s): The secondary efficacy endpoints for this study at 24 weeks postâend of treatment/end of untreated observation are as follows:
1 Seroconversion to anti-HBs (loss of HBsAg and presence of anti-HBs)
2 Seroconversion to anti-HBe (loss of HBeAg and presence of anti-HBe)
3 Loss of HBeAg
4 HBV DNA < 20,000 IU/mL, 2000 IU/mL , undetectable and change from baseline (by PCR or hybridization)
5 Combined endpoints: HBeAg seroconversion and HBV DNA < 20,000 IU/mL
6 Combined endpoints: HBeAg seroconversion and HBV DNA < 2000 IU/mL

At 1 year post-treatment:
7 Seroconversion to anti-HBs (loss of HBsAg and presence of anti-HBs)
8 Seroconversion to anti-HBe (loss of HBeAg and presence of anti-HBe)
9 Loss of HBsAg and HBeAg
10 HBV DNA < 20,000 IU/mL,  < 2000 IU/mL, undetectable and change from baseline (by PCR or hybridization)
11 Combined endpoints: HBeAg seroconversion and HBV DNA  < 20,000 IU/mL
12 Combined endpoints: HBeAg seroconversion and HBV DNA  < 2000 IU/mL
E.5.2.1 Timepoint(s) of evaluation of this end point: 1-6. At 24 weeks postâend of treatment/end of untreated observation
7-12. At 1 year postâtreatment

E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Yes
E.6.7 Pharmacodynamic: Yes
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: No treatment
E.8.2.4 Number of treatment arms in the trial: 2
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 10
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: No
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
Australia
Belgium
Germany
Italy
Malaysia
Romania
Russian Federation
Taiwan
Turkey
Ukraine
United Kingdom
United States
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: The end of the study is defined as the date when the last patient, last visit (LPLV) for the final analysis occurs. LPLV for final analysis at 1 year after the end of treatment is expected to occur approximately 2 years and 2 months after the last patient is enrolled.
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 7
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 7
E.8.9.2 In all countries concerned by the trial months: 0
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: Yes
F.1.1 Number of subjects for this age range: 114
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): Yes
F.1.1.5.1 Number of subjects for this age range: 57
F.1.1.6 Adolescents (12-17 years): Yes
F.1.1.6.1 Number of subjects for this age range: 57
F.1.2 Adults (18-64 years): No
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: Yes
F.3.3.6.1 Details of subjects incapable of giving consent: Children from ages 3 to 17
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 57
F.4.2.2 In the whole clinical trial: 114
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): The Sponsor does not have any plans to provide the Roche IMP PegasysÂ® or any other study treatments or interventions to patients who have completed the study

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2015-10-29
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2015-11-02

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2020-01-29

